Background
==========

The genomic interval that spans chromosome bands 10q24-q25 contains a high frequency of structural chromosome aberrations associated with cancer and development. However, existing published maps around the *PAX2/HOX11/NFKB2*region of 10q24 have differed with respect to marker and gene content, their relative order and chromosomal orientation \[[@B1]-[@B4]\]. More recent inconsistencies in the positioning of selected genes with respect to known markers have also been evident within the context of the human genome databases (Figure [1](#F1){ref-type="fig"}). It is essential to have available an accurate physical map of this region so that disease-related chromosome aberrations can be precisely localized, and to better understand the interplay of regulatory elements associated with genes that map within this domain.

![Order and chromosomal orientation of clones mapped by FISH in this study **(D)**aligned with integrated NCBI maps dynamically changing through the time periods April 2001 (Build 22), August 2001 (Build 25), April 2002 (Build 29) and November 2002 (Build 31) **(A-D)**. Genes and sites relevant to reagents used in this study are shown in bold or in grey-filled boxes, and if not marked, were not found in that particular Build. Also indicated are key STS sites common between previously published maps of this region \[[@B1]-[@B4]\] (C,D). For A and B, only D10S571, D10S1266, *LGI1*, *GOT1*and *WNT8B*are shown, in addition to markers relevant to the reagents of this study (if found) to illustrate major rearrangements of database contigs within this region through the different NCBI Builds. The locations of 7 additional cancer-related genes are indicated in C and D, with the relative locations of clones used in the present study shown aligned with the recently released Build 31 (D) (see Results for further details). Arrowheads above maps B-D correspond to cancer-related chromosome breakpoint sites associated with disruption of the *LGI1*gene \[[@B23],[@B46]\], *HOX11*\[[@B8]-[@B13]\] and *NFKB2/LYT-10*\[[@B21],[@B22]\]. The cancer-related gene *MXI1*\[[@B30]\] maps \~7.5 Mb telomeric of *GERP1*.](1471-2164-4-9-1){#F1}

The 10q24 region harbors several loci of fundamental biological importance, including the *HOX11*(*TLX1,TCL3*), *PAX2*and *NFKB2/LYT-10*genes. *HOX11*is an orphan homeobox gene that maps outside of the four recognized homeobox gene clusters. It encodes a DNA-binding nuclear transcription factor \[[@B5]\], and is involved in spleen organogenesis \[[@B6],[@B7]\]. About 5% of T-cell acute lymphoblastic leukaemias (T-ALL) show chromosome translocations involving break-prone regions immediately upstream of the *HOX11*gene at 10q24 and the TCR genes at 7q35 or 14q11. *HOX11*is activated by TCR α/δ regulatory elements as a result of these rearrangements, and inappropriately expresses a 2.3 kb transcript \[[@B8]-[@B13]\]. *PAX2*is important during embryogenesis, and is aberrantly expressed in renal, breast and prostate tumors \[[@B14]-[@B16]\]. Mutations in *PAX2*are also associated with defects in eye, ear, urogenital tract and CNS development \[[@B17],[@B18]\]. The nuclear factor kappa-B 2 (*NFKB2*) gene is a member of the NFKB/Rel gene family, the signaling pathways of which are recognized as pivotal to the regulation of acute inflammatory and immune responses, and increasingly to tumor development \[[@B19],[@B20]\]. Translocations or structural alterations of *NFKB2*(alias *LYT-10*) have been associated with \~2% of various lymphoid malignancies, and usually result in the partial or total deletion of the carboxyl-terminal region encoding the *ankyrin*domain \[[@B21],[@B22]\].

Positional cloning of a balanced t(10;19)(q24;q13) translocation found in a glioblastoma cell line has identified a new gene, *LGI1*, which is rearranged and downregulated in malignant brain tumors and has recently been implicated in autosomal dominant lateral temporal epilepsy (EPT) \[[@B23]-[@B25]\]. Karyotype, comparative genomic hybridization and loss of heterozygosity studies also indicate that yet to be identified oncogenes or tumor suppressor genes map to 10q24. For example, loss or rearrangement of regions encompassing 10q24 is associated with cancers of the lung \[[@B26],[@B27]\], prostate \[[@B28]-[@B33]\], bladder \[[@B34]-[@B36]\], skin \[[@B37],[@B38]\], and lymphatic system \[[@B39]-[@B41]\]. The human papillomavirus type 6a (HPV6a) was also previously reported to integrate at 10q24 in a case of tonsillar carcinoma, and rearrangements involving this locus have been indicated for other papillomavirus-associated malignancies \[[@B42]\].

As one part of our investigations of a novel leukaemia-related chromosomal translocation (Gough et al, unpublished), we have used a combination of chromosome and interphase FISH, BAC end-sequencing, PCR and genome database analysis to map the order and chromosomal orientation of selected cancer-related genes and the HPV6a viral integration site HPV6AI1 within 10q24. Here we present new data that confirms the order CEN-*CYP2C9-PAX2-HOX11-NFKB2-*TEL. This finding resolves the physical arrangement of larger DNA sequence contigs containing these and at least 9 other genes which have so far been implicated in different cancer subtypes. Our studies further show that HPV6AI1 does not map within 10q24, but at a different chromosomal site, namely at the interface of chromosome bands 14q13.3-q21.1.

Results
=======

Two-Color FISH Establishes Order and Orientation of Genes and Markers at 10q24
------------------------------------------------------------------------------

Selected large-insert clones (refer Methods) were biotin- or digoxygenin-labeled, pooled in combinations of three, then hybridized to G1-arrested interphase nuclei. For each experiment, after signal amplification using FITC- (green) or Texas Red- (red) tagged immunofluorescent reagents, the order of signals from at least 55 chromosomes, and usually 100, was recorded. After exclusion of chromosomes showing ambiguous signal patterns, the predominant order of signals was taken to represent the physical order of the probes along the chromosome (Table [1](#T1){ref-type="table"}, Figure [2a,2b,2c,2d,2e,2f,2g,2h,2i,2j,2k,2l](#F2){ref-type="fig"}). For many combinations, the same three probes were pooled and hybridized twice. For the first of these paired experiments, two probes were labeled with biotin and a third with digoxygenin. For the second, the probe label and detection color was reversed for two of the probes. By this alternation, and through a sequence of different probe combinations, a final arrangement of genes and markers across the 10q24 region was derived (Table [1](#T1){ref-type="table"}, Figures [1d](#F1){ref-type="fig"},[2](#F2){ref-type="fig"}).

![Metaphase **(c,j)**and interphase **(a,b,d-i,k,l)**FISH analysis determines order and relative orientation of selected cancer-related gene probes within 10q24 **(m)**. For interphase figures (a-l), locus identities are indicated in text beneath each representative image, with text color corresponding to the FISH detection color used. Observed frequencies (%) of the probe orders shown are also indicated. Note that the triangular pattern of probes visible on one homologue in a) was classified ambiguous.](1471-2164-4-9-2){#F2}

###### 

Order and Frequency of Probe Signal Patterns on Interphase Nuclei after FISH

  **Probe Combination (Detection Color^1^)**   **Signal Order \[No. scored (%)\]**                                                                     
  -------------------------------------------- ------------------------------------- -------------------------------- ---------- ---------- ---------- ----------
  10D15^b^(R)                                  \+ 10D14^d^(Gr)                       \+ 10E3^b^(R)                    38 (69%)   17 (31%)              
  10D15^b^(R)                                  \+ 10D14^b^(R)                        \+ 10E3^d^(Gr)                   23 (26%)   66 (74%)              
  10D14^b^(R)                                  \+ 10E3^d^(Gr)                        \+ 29CD5 (*PAX2*)^d^(Gr)                               75 (99%)   1 (1%)
  10D14^d^(Gr)                                 \+ 10E3^b^(R)                         \+ 29CD5 (*PAX2*)^d^(Gr)                               25 (30%)   58 (70%)
  10D14^d^(Gr)                                 \+ 10E3^d^(Gr)                        \+ 165f21 (*PAX2*)^b^(R)                               67 (75%)   22 (25%)
  10D14^b^(R)                                  \+ 165f21 (*PAX2*)^b^(R)              \+ CosC2^d^(Gr)                  13 (18%)   61 (82%)              
  10D14^b^(R)                                  \+ 165f21 (*PAX2*)^d^(Gr)             \+ CosC2^d^(Gr)                                        79 (95%)   4 (5%)
  165f21 (*PAX2*)^d^(Gr)                       \+ CosC2^b^(R)                        \+ λSh3F (*HOX11*)^d^(Gr)                              7 (18%)    32 (82%)
  10D14^b^(R)                                  \+ CosC2^d^(Gr)                       \+ λ*lyt*-10 (*LYT-10*)^d^(Gr)                         76 (82%)   17 (18%)
  10D14^b^(R)                                  \+ CosC2^b^(R)                        \+ λ*lyt*-10 (*LYT-10*)^d^(Gr)   22 (25%)   67 (75%)              

^1^R, red; Gr, Green; ^b^Biotin labelled. ^d^Digoxygenin labelled. Probe combinations represented correspond to Figures [2a,2b,2d,2e,2f,2g,2h,2i,2k](#F2){ref-type="fig"} and [2l](#F2){ref-type="fig"}, respectively.

BAC clones 10E3, 10D14 and 10D15 were each first hybridized to normal metaphase chromosomes and confirmed to map to 10q24 (data not shown). Interphase FISH experiments subsequently revealed the clone order 10D15-10D14-10E3 (Table [1](#T1){ref-type="table"}, Figure [2a,2b](#F2){ref-type="fig"}). The chromosomal orientation of this map was determined when the three pooled biotinylated BAC clones were shown to map centromeric of the digoxygenylated YAC clone 29CD5 (*PAX2*) on the majority of metaphase chromosomes 10 analyzed (Figure [2c](#F2){ref-type="fig"}, left), and when BAC 10D15 was similarly shown to map centromeric of BAC 165f21 (*PAX2*) (Figure [2c](#F2){ref-type="fig"}, right). The final centromere-telomere orientation of the BAC clones relative to *PAX2*was established when BACs 10E3 and 10D14 were hybridized in combination with YAC 29CD5 (*PAX2*) or BAC 165f21 (*PAX2*) to interphase nuclei in a series of three different experiments (Table [1](#T1){ref-type="table"}, Figure [2d,2e,2f](#F2){ref-type="fig"}). From this combined data we concluded the preliminary map order centromere-10D15-10D14-10E3-29CD5/165f21/*PAX2*-telomere.

The cosmid C2 (CosC2), reported to contain the HPV6a viral integration site HPV6AI1\[[@B42]\], was next mapped with respect to 10D14 and BAC 165f21(*PAX2*) (Table [1](#T1){ref-type="table"}, Figure [2g,2h](#F2){ref-type="fig"}), indicating the order centromere-10D14-165f21(*PAX2*)-CosC2-telomere (Figure [2m](#F2){ref-type="fig"}). *HOX11*was shown to map close and immediately telomeric of CosC2 when the λSh3F probe (green) was pooled with BAC 165f21 (green) and CosC2 (red), and hybridized to interphase nuclei. This conclusion was based on the predominant green-red-green signal order for this experiment (Table [1](#T1){ref-type="table"}, Figure [2i](#F2){ref-type="fig"}), the already established centromeric location of *PAX2*relative to CosC2 (Figure [2g,2h](#F2){ref-type="fig"}), and the smaller size of the λSh3F (*HOX11*) probe and signal (Figure [2i](#F2){ref-type="fig"}). We note that three cDNA fragments (EMBL:HSAPTB7, EBML:HSAPTL12, EMBL:HSAPTF3) have been isolated from CosC2 and sequenced (NCBI Accession Nos Y11608, Y11609, and Y11610) (Kahn et al, unpublished). Consistent with the above interphase FISH results, BLASTN and Map Viewer <http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi?> analysis confirmed that all of these cDNA fragments map immediately centromeric of *HOX11*in NCBI Build 31.

The *NFKB2*/*LYT-10*locus represented by the probe λ*lyt*-10 mapped telomeric of 10D14 and CosC2 in two interphase experiments, with the second experiment alternating the CosC2 probe label (Table [1](#T1){ref-type="table"}, Figure [2k,2l,2m](#F2){ref-type="fig"}). A final hybridization of pooled biotinylated and digoxygenylated λ*lyt*-10 probe (yellow) with λPAX2 (red) and λSh3F (*HOX11*) (green) to interphase nuclei determined the order red-green-yellow on 24 of 32 (75%) chromosomes analyzed (data not shown), and confirmed that *NFKB2*/*LYT-10*mapped telomeric of *HOX11*.

The final overall map orientation was confirmed when λ*lyt*-10 (green) was shown to hybridize telomeric of BAC 10D15 (red) (Figure [2j](#F2){ref-type="fig"}) on metaphase chromosomes, and although not measured statistically, the distance separating 10D15 and λ*lyt*-10 was visibly greater than that which separates 10D15 and BAC 165f21 (*PAX2*) (compare Figure [2c,2j](#F2){ref-type="fig"}). From these metaphase and interphase FISH studies, we determined the following probe (gene) order within 10q24: centromere-10D15-10D14-10E3-YAC29CD5/BAC165f21(*PAX2*)-CosC2-λSh3F(*HOX11*)-λ*lyt*-10 (*NFKB2*) -telomere (Figure [1d](#F1){ref-type="fig"}, [2m](#F2){ref-type="fig"}).

Chromosome 10 clone CosC2 does not contain the human papillomavirus integration site HPV6AI1 which instead maps to chromosome 14
--------------------------------------------------------------------------------------------------------------------------------

The close proximity of CosC2 and λSh3F (*HOX11*) probes, indicated by a high percentage of overlapping red and green signals (Figure [2i](#F2){ref-type="fig"} and data not shown), was noteworthy in this analysis and suggested that the HPV6AI1 integration site (CosC2) maps closely centromeric and probably \<200 kb of *HOX11*\[[@B43],[@B44]\]. However, genomic database investigations indicated that the 2746 bp of genomic sequence available across HPV6AI1 (NCBI Accession No_X77607; \[[@B42]\]), and that was originally reported to derive from a *Bam*HI-*Bgl*II subclone of CosC2, is not tightly integrated within 10q24 contigs of the genomic databases (eg. NCBI Map View, Build 31, November, 2002), but instead finds significant, if disrupted, homology across nts 1..2341 (98%) and 2334..2735 (94%) to chromosome 14, at the q13.3-q21.1 band interface (NCBI Accession No NT_026437.9, Build 31) (Figure [3c](#F3){ref-type="fig"}). Restriction digests of CosC2 released fragment sizes consistent with reported features of that clone \[[@B42]\] (data not shown), and internal Alu-specific primers A51 (forward) and Sb2ins2 (reverse) confirmed the integrity of CosC2 DNA (Figure [3a](#F3){ref-type="fig"}, left panel, lanes 4--6). However, three PCR primer pairs that were designed to distinguish closely homologous chromosome 14 sequences from those theoretically on 10q24 (Table [2](#T2){ref-type="table"}) failed to amplify products from CosC2 under relaxed primer annealing conditions (52°C, 2 mM Mg++) (Figure [3a](#F3){ref-type="fig"}, right panel, lanes 4--6), but did so from control genomic DNA (Figure [3a](#F3){ref-type="fig"}, right panel, lanes 1--3). Primer pair A (HPV6apr1/HPV6aRev) amplifies a 615 bp product common to both X77607 and homologous chromosome 14 sequence (Figure [3a,3c](#F3){ref-type="fig"}). Primer pairs B (Chr14gapF/Chr14gapR) and C (Chr14endF/Chr14endR) were designed to amplify 535 bp and 699 bp products specific to chromosome 14 sequence as determined by genomic database comparisons (Figure [3a,3c](#F3){ref-type="fig"}). When hybridized to a Southern-blotted human chromosome-specific somatic cell hybrid panel, the 615 bp fragment showed positive signals only in the control and chromosome 14-specific lanes (Figure [3b](#F3){ref-type="fig"}). From these studies we conclude that CosC2 does not contain the 2746 bp viral integration site HPV6AI1 of NCBI Accession X77607, but that this site instead maps to the chromosome band 14q13.3-q21.1 interface. We are unable to explain the 209 bp of sequence that is present on chromosome 14q but not in X77607 (Figure [3c](#F3){ref-type="fig"}). The chromosome 14 \"insertion\" occurs within a L1PREC2 nontransposable repeat element, and may correspond to an insertion/deletion polymorphism although sequence artifact cannot be excluded.

![PCR confirms absence of the HPV6AI1 site in the recombinant cosmid clone CosC2. **(A)**Gel electrophoresis of products amplified from human genomic DNA and CosC2 DNA using PCR primer sets A, B and C, and Alu-specific primers (refer Figure [3C](#F3){ref-type="fig"}, Table [2](#T2){ref-type="table"}). In the *left panel*, lanes 1--3 show genomic DNA fragments amplified with primer sets A (615 bp product), B (535 bp product), and C (699 bp product), all at 1.5 mM Mg++ and annealed at 60°C. Lane 4 shows CosC2 DNA amplified with Alu primers A51/Sb2ins2. Lanes 5 and 6 are, respectively, negative (no DNA) and positive genomic DNA controls for this primer set. Lane N is a negative control (no DNA) for primer set A. In the *right panel*, lanes 1--3 are as in the left panel except that reactions were at 2 mM Mg++ with annealing at 52°C. Note the presence of additional bands in lane 3 under these relaxed stringency PCR conditions. Lanes 4--6, under the same conditions, show no product from the CosC2 template using the primers sets A, B and C respectively. In both left and right panels, M is a 100 bp molecular weight reference ladder. (**B**) Somatic cell hybrid panel showing *Pst*I fragments of \~9.5 kb detected in control male and female genomic DNA lanes, and in the chromosome 14 specific lane (arrow) after hybridization with the ^32^P-dCTP labeled 615 bp fragment amplified using primer set A. λ *Hind*III fragment sizes are indicated to the left of the panel. (**C**) Alignment of the published sequence X77607 with contig NT_026437.9 from chromosome (chr) 14. In the lower figure, the thin grey line corresponds to chr 14 sequence, and thicker solid (repeat-free) or hatched boxes correspond to regions that have overlapping homology with X77607. Repeat sequences identified using CENSOR are shown as diagonal hatched regions corresponding to CHESHIRE_B (narrow downward), LIPB4 (wide upward), L1PREC2 (narrow upward) and THE1B (wide downward). Flanking nt sequence locations are indicated for each contig, as is the location of the HPV6AI1 integration site. Locations of primer pairs A-C are marked by forward (f) and reverse (r) arrows. The bracketed region marks 209 bp of chr 14 sequence not present in X77607.](1471-2164-4-9-3){#F3}

###### 

PCR primer sequences and reaction conditions used to verify localization of *HPV6AI1*

  **Primer ID**   **Locus**    **Primer Sequence (5\' \> 3\')^a^**   **Annealing Temp (°C)**   **Mg++ (mM)**   **Primer Pair ID^b^**
  --------------- ------------ ------------------------------------- ------------------------- --------------- -----------------------
  HPV6apr1        HPV6AI1^c^   F-TTATAGATTCGGGGGTACACACGTAG          60                        1.5             A
  HPV6aRev        HPV6AI1^c^   R-AGCAGAGAAAAGGAATGCCGATAT            60                        1.5             
  Chr14gapF       14q13^d^     F-TCTTGTTAAATTGTTTGAGTTCC             60                        1.5             B
  Chr14gapR       14q13^d^     R-CTATTCTAATCAAAACAGCATGG             60                        1.5             
  Chr14endF       14q13^d^     F-TATTGAATAGAGAGTCCTTTCCC             60                        1.5             C
  Chr14endR       14q13^d^     R-TAAACCTCATCTTGAATTGTAGC             60                        1.5             
  A51             Alu^e^       F-GGCGCGGTGGCTCACG                    65                        1.5             Alu
  Sb2ins2         Alu Sb2^f^   R-GGCCGGACTGCGGACTGCA                 65                        1.5             

a, F = forward, R = reverse; b, as represented in Figure [3](#F3){ref-type="fig"}; c,d derived from NCBI Accession No X77607 and NT_025892.8, respectively; e,f derived from Alu-repeat consensus and AluYb8 (Sb2) subfamily-specific consensus sequences, respectively (Labuda et al, unpublished).

BAC End Sequencing Allows Integration of FISH Results into Genomic 10q24 Map
----------------------------------------------------------------------------

To facilitate the orientation and relative locations of probes used for FISH studies, T7-primed genomic end-sequences of BAC clones 10D14, 10D15 and 10E3 were submitted to BLASTN after identification of repetitive sequences using CENSOR. In the sequence release of Build 31 (November 2002), a 520 bp end-sequence of 10D15 showed 95% homology across nucleotides (nts) 11626039--11626469 of NCBI contig NT_033890.3 (Figure [1d](#F1){ref-type="fig"}), consistent with its most centromeric location in our study (Figure [1d](#F1){ref-type="fig"}). A 700 bp end-sequence of 10D14 showed 98% homology across nts 8367245--8367938 towards the telomeric end of the same contig as 10D15 in Build 29, mapping \~650 bp upstream of the 5\' start of the cytochrome P4502C9 (*CYP2C9*) gene (Figure [1c](#F1){ref-type="fig"} and data not shown). In Build 31, end-sequences of 10D15 and 10D14 (NT_030059.8, nts 1961641--1962337) have been mapped to different juxtaposing contigs. The spatial and chromosomal orientation of 10D15 and 10D14 through these two Builds is, however, consistent with our FISH interphase mapping results, which show that *CYP2C9*maps centromeric of the *PAX2/HOX11/NFKB2*region (Figure [1d](#F1){ref-type="fig"}). Finally, a 650 bp end-sequence of 10E3 showed 99% homology across nts 12098591--12097943 of contig NT_030059.6 in Build 29 (Figure [1c](#F1){ref-type="fig"}). This location is inconsistent with the visibly centromeric location and closer proximity of 10E3 to *PAX2*(YAC 29CD5/BAC 165f21) in interphase FISH experiments (Figure [2c,2d,2e](#F2){ref-type="fig"}), a finding that is more consistent with the relocation in Build 31 of contig NT_030059.8 which contains the 10E3 homologous nts 6881174--6881822 (Figure [1d](#F1){ref-type="fig"}).

Alignment of BACs 10D14, 10D15 and 10E3 end-sequences against 10q24 contigs of earlier NCBI Builds 22 (April 2001), 25 (August 2001) and 29 (April 2002) graphically reflects the dynamically evolving assembly of contigs, genes and markers within this region (compare Figures [1a,1b,1c](#F1){ref-type="fig"}). Our FISH interphase mapping and BAC-end sequencing results fitted best into the current NCBI sequence contigs (NCBI Build 31) (Figure [1d](#F1){ref-type="fig"}), and is also in agreement with the Human Genome Project Working Draft <http://genome.ucsc.edu/> described by the International Human Genome Sequencing Consortium \[[@B45]\]. The relative locations of 9 other genes reported to be structurally or functionally implicated in malignancy, including *LGI1*\[[@B23],[@B46]\], *FRAT1*\[[@B47]\], *FRAT2*\[[@B48]\], *WNT8B*\[[@B49]\], *LAPSER1*\[[@B32]\], *FGF8*\[[@B50]\], *MGEA5*\[[@B51]\], *SUFU*\[[@B52]\] and *GERP*(*TRIM8*) \[[@B53]\], the STS markers D10S583, D10S571, D10S198, D10S603, D10S1266, D10S192, D10S278, D10S1265 and the gene *GOT1*were determined by BLASTN comparison of deposited sequences against the NCBI databases (Figure [1c,1d](#F1){ref-type="fig"}).

Discussion
==========

Using interphase FISH we have determined the relative order of selected cancer-related genes that map within chromosome band 10q24. This analysis, complemented by BAC end-sequencing and genomic database analysis, has also established the chromosomal orientation of NCBI nucleotide contigs that contain these genes, and which span \~11 Mb. The gene and marker order that we have determined is centromere-BAC10D15-BAC10D14/CYP2C9-BAC10E3-*PAX2*-CosC2-*HOX11*-*NFKB2/LYT-10*-telomere. The order of genes and markers on our map differs from the NCBI release of Build 29, and is more consistent with previous NCBI releases including Build 25, with the June 2002 freeze of the UCSC Human Genome Project Working Draft <http://genome.ucsc.edu/> and with the more recently released NCBI Build 31.

There have been several published studies designed to clarify the physical map across 10q24 \[[@B1]\], although none have specifically focussed on the order and orientation of cancer-related genes or sites of inter- and intra-chromosomal rearrangement involving this region. In one of these reports, Gray et al applied a combination of metaphase FISH (to confirm 10q24 map location) and PCR amplification of microsatellite, STS and other known gene markers to the analysis of a series of overlapping YACs spanning \~15 Mb of DNA \[[@B1]\]. Of particular interest, Gray et al noted a high frequency of rearranged YACs (4/5 analysed) distal to D10S574 and incorporating the *GOT1*, *WNT8B*and *PAX2*gene cluster. That feature, combined with the inability to isolate YAC clones immediately telomeric of this region, a known BrdU-inducible fragile site in 10q24-q25, and chromosome translocation breakpoint clusters associated with ALL and other lymphoproliferative neoplasms is suggestive of inherent instability of this chromosomal segment \[[@B1]\]. To date, although chromosomal imbalances involving this region are prevalent across a wide variety of different cancer subtypes, the genomic basis for this instability has yet to be explained.

In the separate study of Nikali and colleagues, which was designed to refine the map location of the IOSCA locus at 10q24, a similar map configuration was derived \[[@B2]\]. For this study, radiation hybrid analysis was used to determine the order of selected microsatellite and other known STS or gene markers, including *PAX2*, across a \>500 kb region between D10S198 and D10S222 \[[@B2]\]. Fibre-FISH was also used to confirm the order and orientation of selected clones within the IOSCA region but did not confirm chromosomal orientation of the contig under study \[[@B2]\].

Neither of the above two studies, nor others reported subsequently \[[@B4],[@B54]-[@B56]\], have provided unequivocal evidence of the centromere-telomere orientation of *PAX2*, *HOX11*and *NFKB2/LYT-10*within the 10q24 region that we have targeted. Nor do they include analyses that convincingly demonstrate the relative location of these and other cancer-related genes across this region. Most published investigations to date have used YAC clones and microsatellite analysis to map the 10q24 region, or have referenced maps constructed with YACs. However, the reported propensity for YACs derived from this region to undergo internal rearrangement and deletions may have contributed to map inconsistencies. The information we have presented is based mostly on smaller insert BAC, cosmid and bacteriophage clones. Our clarification of the 10q24 physical map is complementary to the International Human Genome Sequencing Consortium BAC-derived assemblies hosted by the NCBI, and will enable more precise mapping of chromosome translocation breakpoints or other structural rearrangements associated with malignant and nonmalignant disease conditions.

Our FISH studies show that the cosmid clone CosC2 maps close, centromeric and upstream of the homeobox gene *HOX11*. This finding was of interest because CosC2 reportedly contains the HPV6a viral integration site HPV6AI1 previously associated with an infiltrating squamous cell carcinoma of the tonsil \[[@B42]\], and suggested that deregulation of *HOX11*by the integration process may have been implicated in this malignancy. However, genomic database analysis of sequences that did not derive specifically from the germline CosC2 insert but which directly flank the previously described HPV6a integration site indicates that HPV6AI1 maps not to 10q24 but to the interface of chromosome band 14q13.3-q21.1. Further database analysis showed that HPV6a integration occurred within a L1PB4 nontransposable repeat, and between the predicted coding domains of FLJ30803 and LOC122529 (data not shown). This location was confirmed by subsequent PCR and somatic cell hybrid investigations. We presume that the cosmid clone C2 was spuriously selected during the original screening process, for which a probe derived from the sequenced region X77607 was used \[[@B42]\].

The human papillomaviruses (HPVs) are a diverse family that type-specifically infects distinct subsets of epithelial cells. The HPV genome persists as an extrachromosomal episome in non- or premalignant tissues, whereas in invasive cancers, the viral DNA typically integrates into the host genome. This event has been shown to increase stability of HPV16 E6 and E7 mRNAs \[[@B57]\]. Recent evidence suggests that HPV integration sites associated with malignancy are distributed widely across the human genome rather than preferentially localized \[[@B58]-[@B60]\]. However, there is a recognized propensity for HPV DNA integration to occur in or near fragile sites, translocation breakpoint sites, oncogenes or the coding regions of as yet poorly characterized genes that may have relevance to cancer progression \[[@B59]-[@B65]\]. Although HPV6AI1 does not appear to interrupt a coding domain, it is of interest that the HPV6AI1 site falls within a repeat element and close to a possible insertion/deletion polymorphism site on chromosome 14. These findings are consistent with the highly recombinogenic/unstable regions in which papillomavirus integrations are predicted to occur.

Previously published studies of the HPV6a integration site we have relocalized showed that the corresponding normal allele was not present in the originally characterized tonsillar carcinoma cells \[[@B42]\]. Rearrangements in the region of the HPV6a integration site were also implicated by Southern blot analysis of a limited number of other tumors, including 2 of 25 genital condylomas, and 2 (1 tonsillar, 1 hypopharnyx) of 7 head and neck tumors tested \[[@B42]\]. Together, these findings were suggestive that the HPV6a genome had disrupted a novel cancer-related gene or gene regulatory region at 10q24. However, analyses reported here indicate that this site instead maps to 14q13.3-q21.1, and that loci FLJ30803 and LOC122529 may be two such candidate genes. Further investigations of the chromosome 14 integration site are necessary to verify its functional relevance to HPV-related malignancies.

Conclusions
===========

We have applied chromosome and interphase fluorescent in situ hybridization (FISH), BAC end-sequencing, PCR and genome database analysis to map the order and chromosomal orientation of selected cancer-related genes within chromosome band 10q24, and the human papillomavirus Type 6a (HPV6a) viral integration site HPV6AI1. The 10q24 region is already known to harbor several well studied cancer-related genes, but published cytogenetic, comparative genomic hybridization, allelotyping and other molecular studies suggest that yet to be identified genes relevant to cancer initiation and progression map within this domain. Towards this end it is vital to establish a definitive genetic map of this region, which to date has shown considerable volatility through time in published works of scientific journals, within different builds of the same international genomic database, and across the differently constructed databases. This volatility has proved an ongoing frustration for positional cloning efforts such as those we are pursuing, and it is for this reason that we found the present study necessary. We describe new data that confirms the order CEN-*CYP2C9-PAX2-HOX11-NFKB2*-TEL. This finding resolves the physical arrangement of larger DNA sequence contigs containing these and at least 10 other genes which have so far been implicated in different cancer subtypes. Furthermore, our studies show that the viral integration site HPV6AI1 does not map within 10q24, but at a different chromosomal site, namely at the interface of chromosome bands 14q13.3-q21.1. This is a significant finding and important to report because the HPV6AI1 integration site, originally isolated from a tonsillar carcinoma, was shown to be rearranged in other HPV6a-related malignancies, including 2 of 25 genital condylomas, and 2 of 7 head and neck tumors tested (Kahn et al, 1994, *Cancer Res*. **54**: 1305--1312). Our finding shifts the focus of this genomic interest from 10q24 to a site on chromosome 14 that may potentially harbor a gene with an as yet undetermined role in the etiology of carcinogenesis.

Methods
=======

Genomic clones
--------------

Recombinant YAC, BAC and bacteriophage lambda clones were used to determine the relative order and orientation of the *CYP2C9*, *NFKB2/LYT-10*, *HOX11*and *PAX2*gene loci, and the HPV6AI1 integration site. BAC clones 10D15, 10D14 and 10E3 were selected from the Cedars-Sinai Medical Center Genomic Reagents Resource database <http://www.csmc.edu/genetics/korenberg/int-bac-sts.html> based on their preliminary map location at 10q24 \[[@B66]\]. BAC clone 165f21, which contains the *PAX2*gene, was kindly gifted by Dr K. Nikali (National Public Health Institute, Helsinki, Finland), and YAC clone 29CD5 was isolated from the ICRF YAC library using PCR primers specific for *PAX2*(Eccles et al, unpublished). Genomic lambda (λ) clones of *PAX2*(λPAX2) and *HOX11*(λSh3F) were also isolated from a genomic liver library constructed in λGem-11 (Promega, Madison, WI). Radioactively labelled probes used to screen the λ library as previously described were pG3a \[[@B67]\] and Sh3F \[[@B9]\] for *PAX2*and *HOX11*, respectively. The phage clone λ*lyt*-10 contains a 12 kb genomic fragment including the entire *NFKB2/LYT-10*coding sequence \[[@B68]\]. The previously described cosmid clone CosC2 is reported to contain the viral integration site HPV6AI1 \[[@B42]\].

Fluorescent In Situ Hybridization (FISH)
----------------------------------------

Procedures used, including preparation of metaphase or interphase nuclei from peripheral blood or G1 fibroblasts, slide pre-treatment, probe labeling with biotin or digoxygenin, repeat suppression, hybridization parameters, and single- or two-color immuno-fluorescent detection of labeled probes, were essentially as described \[[@B69],[@B70]\]. Fluorescent images from metaphase or interphase cells were captured at selective bandwidths to computer using a Leitz Aristoplan microscope fitted with a Photometrics KAF1400 CCD camera and QUIPS Smartcapture software (version 1.3; Vysis Inc, Downers Grove, IL, USA). Probes were mapped precisely to chromosome bands in metaphase cells, or relative to each other in interphase cells, using color-joined DAPI, FITC and Texas Red images, and QUIPS CGH/Karyotyping software (version 3.0.2). To avoid damaged cells, metaphase and G1 interphase nuclei were initially selected for analysis under a DAPI-selective filter. G1 interphase nuclei were subsequently scored only if red or green signals corresponding to all probes hybridized were distinguishable on both homologues.

Polymerase Chain Reaction (PCR)
-------------------------------

Primer sequences designed to amplify HPV6AI1, the homologous region on chromosome 14q and a control internal Alu-specific 260 bp fragment are as listed in Table [2](#T2){ref-type="table"}. PCR reactions contained 100 ng of template DNA, 200 μM dNTPs, 500 nM of each primer, reaction buffer (50 mM KCl, 10 mM Tris pH 8.3, 1.5 or 2.0 mM MgCl~2~) and 0.5 units Platinum™ Taq DNA polymerase (Life Technologies). Following 30 cycles of amplification \[denaturation 95°C, 30 sec; annealing (refer Table [2](#T2){ref-type="table"}), 30 sec, extension 72°C, 30 sec\], the PCR products were electrophoresed in 1.5% agarose gels and visualized by ethidium bromide staining. Products were transferred to Hybond N^+^nylon membrane (Amersham, Buckinghamshire, UK) and hybridized with Rediprime random-prime ^32^P-labeled probes (Amersham) following the manufacturer\'s instructions. Control human genomic DNA for PCR studies was extracted from healthy subjects using methods previously described \[[@B71]\].

Somatic Cell Hybrid Analysis
----------------------------

A Southern blot containing *Pst*I digested genomic DNA from a human-rodent somatic cell hybrid panel was obtained from Oncor (Gaithersburg, MD) and hybridized with ^32^P-dCTP-labeled DNA fragments as outlined above.

BAC DNA End-Sequencing
----------------------

End-sequencing of BAC clones 10D14, 10D15 and 10E3 (cloning vector pBAC108L; Shizuya et al., 1992) was performed using ThermoSequenase (Amersham) and a universal T7 IRD41-labeled primer (MWG Biotech, Germany) essentially according to the manufacturers recommendations. Reactions were separated on a LICOR 4000L semi-automated DNA sequencer, and nucleotide sequences subsequently submitted to BLASTN for homology determination.

Genomic Database Resources
--------------------------

Genomic database resources utilized early in this study include the GTC Integrated STS Map <http://www.genomecorp.com>; <http://ihg.gsf.de/chr10/report_text.html#parti>, the Southhampton Integrated Map <ftp://cedar.genetics.soton.ac.uk/pub/chrom10/gmap>, the Whitehead YAC contig WC10.8 <http://www-genome.wi.mit.edu/cgi-bin/contig/lookup_contig> and the NCBI GeneMap 98 <http://www.ncbi.nlm.nih.gov/genemap98/map.cgi?CHR=10>. The International Human Genome Sequencing Consortium assemblies of the Human Genome sequence hosted by the NCBI <http://www.ncbi.nlm.nih.gov/genome/guide/human/release_notes.html>\[[@B43]\], including NCBI MapViewer Builds 22, 25, 29 and 31 corresponding to releases of April 2001, August 2001, April 2002, and November 2002 respectively, were additional sources of data complementary to our findings presented in Figure [1](#F1){ref-type="fig"}. Repeat sequences were identified within the BAC end-sequences and in the HPV6AI1 integration site using CENSOR <http://www.girinst.org/Censor_Server.html> prior to BLASTN homology searches <http://ncbi.nlm.nih.gov/BLAST>.
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